Breast Cancer SABCS 2022: monarchE Trial of Abemaciclib Plus ET for HR-Positive, HER2-Negative, Node-Positive, High-Risk Early Breast Cancer
Breast Cancer SABCS 2022: First-Line Ribociclib Plus Endocrine Therapy in Patients With Aggressive Breast Cancer
Breast Cancer ESMO 2022: Sacituzumab Govitecan for Patients With HR-Positive HER2-Negative Metastatic Breast Cancer
Breast Cancer ASCO 2022: Sacituzumab Govitecan-hziy for HR-Positive/HER2-Negative Advanced Breast Cancer
Breast Cancer Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Previously Treated Metastatic HER2-Positive Breast Cancer
Breast Cancer MONALEESA-2: Final Overall Survival Results With the Addition of Ribociclib to Letrozole in Postmenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer KEYNOTE-522: Event-Free Survival With Neoadjuvant and Adjuvant Pembrolizumab for Triple-Negative Breast Cancer
